A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 194
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : AECB
Long Form : acute exacerbations of chronic bronchitis
No. Year Title Co-occurring Abbreviation
2021 Prulifloxacin Effectiveness in Moderate-to-Severe Acute Exacerbations of Chronic Bronchitis: Α Noninterventional, Multicentre, Prospective Study in Real-Life Clinical Practice-The "AIOLOS" Study. ---
2021 The association between fine particulate matter and acute lower respiratory infections in Yancheng City, China. AEB, AECOPD, ALRI, CAP
2020 Impact of safety warnings for fluoroquinolones on prescribing behaviour. Results of a cohort study with outpatient routine data. ABS, CAP, RR
2020 [Meta-analysis of randomized controlled trials on effect of Tanreqing Injection combined with Western medicine on acute exacerbation of chronic bronchitis]. ---
2017 Efficacy and safety of HL301 in the treatment of acute bronchitis and acute exacerbation of chronic bronchitis: a phase 2, randomized, double-blind, placebo-controlled, multicenter study. AB, BSS, FAS, PPS
2015 Ambient temperature and outpatient visits for acute exacerbation of chronic bronchitis in Shanghai: a time series analysis. CI
2015 SAFETY AND EFFECTIVENESS OF AZITHROMYCIN IN THE TREATMENT OF LOWER RESPIRATORY INFECTIONS: AN INTERNATIONAL, MULTICENTER, NON-COMPARATIVE STUDY. CAP
2014 Characterisation of a collection of Streptococcus pneumoniae isolates from patients suffering from acute exacerbations of chronic bronchitis: in vitro susceptibility to antibiotics and biofilm formation in relation to antibiotic efflux and serotypes/serogroups. SG, ST
2014 Efficacy and safety of moxifloxacin in acute exacerbations of chronic bronchitis and COPD: a systematic review and meta-analysis. CE, CI, ITT, OR
10  2013 Cefditoren versus levofloxacin in patients with exacerbations of chronic bronchitis: serum inflammatory biomarkers, clinical efficacy, and microbiological eradication. KL-6
11  2013 Efficacy and safety of moxifloxacin in acute exacerbations of chronic bronchitis: a prospective, multicenter, observational study (AVANTI). TEAEs
12  2013 Moxifloxacin in lower respiratory tract infections: in silico simulation of different bacterial resistance and drug exposure scenarios. ---
13  2013 Utility of NT-proBNP for identifying LV failure in patients with acute exacerbation of chronic bronchitis. AUC, ESC, HF, LV
14  2012 Bronchopulmonary pharmacokinetic and pharmacodynamic profiles of levofloxacin 750mg once daily in adults undergoing treatment for acute exacerbation of chronic bronchitis. AM, ELF
15  2012 Gemifloxacin for the treatment of community-acquired pneumonia and acute exacerbation of chronic bronchitis: a meta-analysis of randomized controlled trials. CAP, RCTs
16  2012 Levofloxacin for the treatment of respiratory tract infections. CAP, HAP
17  2011 A multicentre surveillance study on the characteristics, bacterial aetiologies and in vitro antibiotic susceptibilities in patients with acute exacerbations of chronic bronchitis. ---
18  2011 Clinical effectiveness and safety of gemifloxacin versus cefpodoxime in acute exacerbation of chronic bronchitis: A randomized, controlled trial. AEs, CGI
19  2010 A phase II study of antofloxacin hydrochloride, a novel fluoroquinolone, for the treatment of acute bacterial infections. AP
20  2010 Antibiotics in acute exacerbations of chronic bronchitis. ---
21  2010 Clinical efficacy of farcosolvin syrup (ambroxol-theophylline-guaiphenesin mixture) in the treatment of acute exacerbation of chronic bronchitis. CGIC
22  2010 Greatest International ANtiinfective Trial (GIANT) with moxifloxacin in the treatment of acute exacerbation of chronic bronchitis: subanalysis of Chinese data of a global, multicenter, noninterventional study. GIANT, MXF
23  2010 Short-course fluoroquinolone therapy in exacerbations of chronic bronchitis and COPD. COPD
24  2010 Short-course fluoroquinolones in acute exacerbations of chronic bronchitis. ---
25  2009 Antibacterial activity of telithromycin and comparators against pathogens isolated from patients with community-acquired respiratory tract infections: the Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin study year 5 (2003-2004). CAP
26  2009 Characterisation of exacerbations of chronic bronchitis and COPD in Europe: the GIANT study. COPD
27  2009 Cost and clinical consequence of antibiotic non-adherence in acute exacerbations of chronic bronchitis. GCG, PCG
28  2009 Gemifloxacin use in the treatment of acute bacterial exacerbation of chronic bronchitis. MIC
29  2009 Treatment of acute bacterial exacerbations of chronic bronchitis. ---
30  2009 [Cefditoren and community-acquired lower respiratory tract infections (corrected)]. CAP, MIC
31  2008 A disease model descriptive of progression between chronic obstructive pulmonary disease exacerbations and community-acquired pneumonia: roles for underlying lung disease and the pharmacokinetics/pharmacodynamics of the antibiotic. AUIC, CAP, COPD, GOLD
32  2008 An evaluation of the effects of gatifloxacin on glucose homeostasis. CAP, CI, OR
33  2008 Appropriateness of antibiotic prescribing in veterans with community-acquired pneumonia, sinusitis, or acute exacerbations of chronic bronchitis: a cross-sectional study. aOR, CAP, MAI, RTIs
34  2008 Costs of treating lower respiratory tract infections. CAP, LRTIs, MCO
35  2008 Faropenem medoxomil: A0026, BAY 56-6854, BAY 566854, faropenem daloxate, SUN 208, SUN A0026. ABS, AOM, CAP
36  2008 Short- versus long-duration antimicrobial treatment for exacerbations of chronic bronchitis: a meta-analysis. CI, RCTs, RR
37  2008 Telithromycin in the treatment of acute bacterial sinusitis, acute exacerbations of chronic bronchitis, and community-acquired pneumonia. ABS, CAP
38  2008 Use of cethromycin, a new ketolide, for treatment of community-acquired respiratory infections. CAP
39  2007 Acute exacerbations of chronic bronchitis in elderly patients: pathogenesis, diagnosis and management. CB, COPD
40  2007 Daily-practice treatment of acute exacerbations of chronic bronchitis with moxifloxacin in a large cohort in Germany. RTIs
41  2007 Faropenem: review of a new oral penem. ABS, CAP, uSSSIs
42  2007 Indicators of bacterial infection in patients with acute exacerbation of chronic bronchitis for application in clinical trials of antibacterial drugs. ---
43  2007 Role of oral extended-spectrum cephems in the treatment of acute exacerbation of chronic bronchitis. ---
44  2007 The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials. CAP, CDN
45  2007 Treating acute exacerbations of chronic bronchitis and community-acquired pneumonia: how effective are respiratory fluoroquinolones? CAP
46  2006 Acute exacerbation of chronic bronchitis: expanding short-course therapy. CI, FEV1
47  2006 Antibiotic treatment and factors influencing short and long term outcomes of acute exacerbations of chronic bronchitis. FEV1, HR, OR
48  2006 Development of a COPD severity score. COPD
49  2006 Discrepancy between antibiotics administered in acute exacerbations of chronic bronchitis and susceptibility of isolated pathogens in respiratory samples: multicentre study in the primary care setting. MIC
50  2006 Effect of pneumococcal vaccination: a comparison of vaccination rates in patients with bacteremic and nonbacteremic pneumococcal pneumonia. ---
51  2006 Efficacy and safety of 3-day azithromycin versus 5-day moxifloxacin for the treatment of acute bacterial exacerbations of chronic bronchitis. AE
52  2006 Eradication of H. influenzae in AECB: A pooled analysis of moxifloxacin phase III trials compared with macrolide agents. ---
53  2006 Moxifloxacin versus levofloxacin against acute exacerbations of chronic bronchitis: the Latin American Cohort. ---
54  2006 Pharmacokinetic and pharmacodynamic aspects of oral moxifloxacin 400 mg/day in elderly patients with acute exacerbation of chronic bronchitis. MIC, PDBPs
55  2006 Respiratory tract infections: at-risk patients, who are they? Implications for their management with levofloxacin. CAP
56  2006 The workplace impact of acute exacerbations of chronic bronchitis (AECB); A literature review. ---
57  2006 [Antibiotic therapy for exacerbation]. ---
58  2005 A review of guidelines for antibacterial use in acute exacerbations of chronic bronchitis. ---
59  2005 Acute exacerbation of chronic bronchitis: need for an evidence-based approach. ICU
60  2005 Antibiotic activity of telithromycin and comparators against bacterial pathogens isolated from 3,043 patients with acute exacerbation of chronic bronchitis. ---
61  2005 Antimicrobial resistance in Haemophilus influenzae: how can we prevent the inevitable? Commentary on antimicrobial resistance in H. influenzae based on data from the TARGETed surveillance program. ---
62  2005 Antimicrobial treatment of lower respiratory tract infections in the hospital setting. CAP, HAP, HCAP, RTIs, VAP
63  2005 Appropriate outpatient treatment of acute bacterial exacerbations of chronic bronchitis. CARAT, COPD
64  2005 Clinical significance of the infection-free interval in the management of acute bacterial exacerbations of chronic bronchitis. ABECB, IFI
65  2005 Effectiveness and cost-effectiveness of antibiotic treatments for community acquired pneumonia (CAP) and acute exacerbations of chronic bronchitis (AECB). CAP, LRTIs, RAMQ
66  2005 Five-day telithromycin once daily is as effective as 10-day clarithromycin twice daily for the treatment of acute exacerbations of chronic bronchitis and is associated with reduced health-care resource utilization. TOC
67  2005 Gatifloxacin: a review of its use in the treatment of bacterial infections in the US. CAP, MDRSP, UTIs
68  2005 Once-daily azithromycin for 3 days compared with clarithromycin for 10 days for acute exacerbation of chronic bronchitis: a multicenter, double-blind, randomized study. MITT, TOC
69  2005 Population antibiotic susceptibility for Streptococcus pneumoniae and treatment outcomes in common respiratory tract infections. AOM, RTIs
70  2005 Prospective observational study of patient-reported outcomes for azithromycin versus usual care in the treatment of bacterial acute exacerbation of chronic bronchitis. AZM, EOS, HRQoL, SGRQ, UC
71  2005 Prulifloxacin: a new fluoroquinolone for the treatment of acute exacerbation of chronic bronchitis. ---
72  2005 Spotlight on cefditoren pivoxil in bacterial infections. CAP
73  2005 Telithromycin in the treatment of pneumococcal community-acquired respiratory tract infections: a review. CAP, RTIs
74  2005 Telithromycin: the first ketolide antimicrobial. AMS, CAP, FDA, RTIs
75  2005 The quality of life impact of acute exacerbations of chronic bronchitis (AECB): a literature review. COPD, HRQL
76  2005 The role of Bordetella infections in patients with acute exacerbation of chronic bronchitis. ---
77  2005 Treatment of acute exacerbations of chronic bronchitis: antibiotic therapy. ---
78  2004 A randomized, double-blind study comparing 5 days oral gemifloxacin with 7 days oral levofloxacin in patients with acute exacerbation of chronic bronchitis. ITT, PP
79  2004 Acute exacerbation of chronic bronchitis: a primary care consensus guideline. ---
80  2004 Antimicrobial selection for community-acquired lower respiratory tract infections in the 21st century: a review of gemifloxacin. CAP, LRTIs
81  2004 Cefditoren pivoxil: a review of its use in the treatment of bacterial infections. CAP
82  2004 Clarithromycin extended-release tablet: a review of its use in the management of respiratory tract infections. CAP
83  2004 Efficacy and safety of pharmacokinetically enhanced amoxicillin-clavulanate at 2,000/125 milligrams twice daily for 5 days versus amoxicillin-clavulanate at 875/125 milligrams twice daily for 7 days in the treatment of acute exacerbations of chronic bronchitis. CI, PP
84  2004 Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitis. ---
85  2004 Gemifloxacin: a new fluoroquinolone approved for treatment of respiratory infections. CAP
86  2004 Moxifloxacin: a review of its use in the management of bacterial infections. CAP
87  2004 New insights in the treatment by levofloxacin. CAP
88  2004 Performance in practice: bacteriological efficacy in patients with drug-resistant S. pneumoniae. ABS, CAP, ITT, PP
89  2004 Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. CI, ITT, PP
90  2004 Telithromycin. ABS, CAP
91  2004 [Acute exacerbation of chronic bronchitis: patients, antibiotherapy, and guidelines]. AB, CB
92  2004 [Mucoregulators in acute bronchitis syndromes: focus on use by general practitioners and data from the literature]. AB, GPs
93  2003 A comparison of 5-day courses of dirithromycin and azithromycin in the treatment of acute exacerbations of chronic obstructive pulmonary disease. COPD
94  2003 A pooled analysis of telithromycin in the treatment of community-acquired respiratory tract infections in adults. AMS, CAP, RTIs
95  2003 An open-label, randomized, multicenter, comparative study of the efficacy and safety of 7 days of treatment with clarithromycin extended-release tablets versus clarithromycin immediate-release tablets for the treatment of patients with acute bacterial exacerbation of chronic bronchitis. AEs, ER, IR
96  2003 Canadian guidelines for the management of acute exacerbations of chronic bronchitis. ---
97  2003 Efficacy and safety of levofloxacin in the context of other contemporary fluoroquinolones: a review. CAP, PK/PD
98  2003 Efficacy and safety of short course (5-day) moxifloxacin vs 7-day ceftriaxone in the treatment of acute exacerbations of chronic bronchitis (AECB). CRO, INHS, ITT, MXF
99  2003 Efficacy and tolerability of moxifloxacin in 2338 patients with acute exacerbation of chronic bronchitis. PMS
100  2003 Equal effectiveness of older traditional antibiotics and newer broad-spectrum antibiotics in treating patients with acute exacerbations of chronic bronchitis. ---